<code id='B1FFFFF2B1'></code><style id='B1FFFFF2B1'></style>
    • <acronym id='B1FFFFF2B1'></acronym>
      <center id='B1FFFFF2B1'><center id='B1FFFFF2B1'><tfoot id='B1FFFFF2B1'></tfoot></center><abbr id='B1FFFFF2B1'><dir id='B1FFFFF2B1'><tfoot id='B1FFFFF2B1'></tfoot><noframes id='B1FFFFF2B1'>

    • <optgroup id='B1FFFFF2B1'><strike id='B1FFFFF2B1'><sup id='B1FFFFF2B1'></sup></strike><code id='B1FFFFF2B1'></code></optgroup>
        1. <b id='B1FFFFF2B1'><label id='B1FFFFF2B1'><select id='B1FFFFF2B1'><dt id='B1FFFFF2B1'><span id='B1FFFFF2B1'></span></dt></select></label></b><u id='B1FFFFF2B1'></u>
          <i id='B1FFFFF2B1'><strike id='B1FFFFF2B1'><tt id='B1FFFFF2B1'><pre id='B1FFFFF2B1'></pre></tt></strike></i>

          hotspot

          hotspot

          author:fashion    Page View:43318
          Adam's take main illustration
          Molly Ferguson/STAT

          The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

          The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

          advertisement

          Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’
          Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

          ActorKevinSpacey,right,arrivesatSouthwarkCrownCourtwhereheisaccusedofsexualoffensesagainstfourmeninB

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          Condition critical? Britain's beloved but battered National Health Service turns 75

          Britain'sPrimeMinisterRishiSunakspeaks,duringtheNHSanniversaryceremonyatWestminsterAbbey,partofthehe